Skip to main content
NewslettersWatchlist

23Andme Holding Co.(ME-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.3170
Day High0.3600
Open:0.3320
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
the globe and mail

23andMe settles data breach lawsuit for $30 million

The lawsuit accused the genetics testing company of failing to protect the privacy of 6.9 million customers whose personal information was exposed in a data breach last year
Reuters
23andMe settles data breach lawsuit for $30 million
Motley Fool
3 Ultra-High-Yield Dividend Stocks to Buy Hand Over Fist Right This Instant
Motley Fool
Why 23andMe Stock Tumbled 10% on Tuesday
Motley Fool
This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
Motley Fool
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
Motley Fool
A Few Years From Now, You'll Probably Wish You'd Followed Billionaire Investors Into This Stock
Motley Fool
Is 23andMe Stock a Smart Buy Right Now?
Motley Fool
The 3 Worst Stock Investments I Ever Made -- and What I Learned From Them
Newsfile
INVESTIGATION ALERT: Levi & Korsinsky, LLP Announces Investigation Of 23andMe Holding Co (ME) Data Breach
BayStreet.ca
Why Pancreatic Cancer is No Longer a Death Sentence: Emerging Therapies to Watch
Motley Fool
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
Motley Fool
Why 23andMe Holding Stock Plummeted by 13% Today
PR Newswire
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating 23andMe Holding Co. for Potential Breaches of Fiduciary Duty By Its Board of Directors
Motley Fool
Better Diversified Biotech Stock: 23andMe vs. Fulgent Genetics
Motley Fool
3 Key Biotech Trends for 2023 And Beyond
PR Newswire
23andMe Publishes Inaugural Environmental, Social and Governance Report
Motley Fool
3 Key Ways That Artificial Intelligence Will Disrupt Biotech Stocks
Motley Fool
AI Revolution on the Horizon: 2 High-Potential Growth Stocks to Watch in 2023
Motley Fool
2 Undervalued Growth Stocks With Long-Term Prospects That Are Ready to Rise
Motley Fool
2 High-Growth Stocks That Could Double Your Money in 5 Years or Less
Motley Fool
This Genetics Stock Could Have Massive Long-Term Potential
Motley Fool
7 Former SPACs I Still Own (And What I Think Now)

Profile

23andMe Inc. is a consumer genetics and research company. It involved in discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory and cardiovascular diseases, in addition to other therapeutic areas. 23andMe Inc., formerly known as VG Acquisition Corp., is headquartered in Sunnyvale, CA.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.